-
Delta variants are in vogue, but could this variant be more deadly?
Time of Update: 2021-09-05
According to the cohort data published by Professor Abu-Raddad on the preprint server medRxiv, among patients with similar characteristics such as age and gender, compared with the Alpha variant, the possibility of developing a serious disease after being infected with the Beta variant is increased by nearly 25%.
-
Approximately 70% of skin tumors have shrunk significantly
Time of Update: 2021-09-05
On August 12, 2021, Medivir announced that its topical histone deacetylase (HDAC) inhibitor remetinostat has obtained positive results in a phase 2 clinical trial for adjuvant treatment of patients with basal cell carcinoma (BCC) .
Retrieved August 12, 2021, from https:// remetinostat-phase-ii-study-in-basal-cell-carcinoma-published-in-clinical-cancer-research-301354426.
-
How the key toxic protein of Alzheimer's disease is formed, new research points out the importance of acid-base environment
Time of Update: 2021-09-05
▲Endosomes and lysosomes are the key sites that affect Aβ assembly in cells (picture source: reference [1])The researchers also observed that with the increase of toxic Aβ oligomers, the mislocalization of another protein, tau, appeared in nerve cells, a protein closely related to the progression of Alzheimer's disease .
-
The fatality rate has increased by 82%. Will these new crown mutant strains become the next Delta?
Time of Update: 2021-09-05
21261465The results of the study show that compared with the Alpha variant, the Beta variant infection causes a 24% higher risk of severe illness, a 49% higher probability of developing to require intensive care, and a 57% higher risk of death .
-
Treating neurodegenerative diseases with US$90 million to help develop TREM2 targeted therapy
Time of Update: 2021-09-05
Reference materials:[1] Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases.
Retrieved August 18, 2021, from https:// /en/Vigil-Neuroscience-Completes-90-million-Series-B-Financing-to-Advance-a-Pipeline-of-Microglia-targeted-Medicines-to-Treat-Rare-and-Common-Neurodegenerative-Diseases(The original text has been deleted)
-
U.S. FDA approves Pfizer vaccine to prevent tick-borne encephalitis
Time of Update: 2021-09-05
Pfizer recently announced that the US FDA has approved TicoVac (tick-borne encephalitis vaccine) for the prevention of tick-borne encephalitis (TBE) in individuals over 1 year old .
The press release states that TicoVac is the first TBE vaccine approved by the US FDA .
-
Highlights of "Cell": Prevent vision loss!
Time of Update: 2021-09-05
▲The optic nerve composed of axons of retinal ganglion cells transmits visual signals to the brain's visual processing center (picture source: reference material [3]; Credit: National Eye Institute)"In order to preserve vision, we urgently need strategies that can protect nerves to retain fragile retinal ganglion cells .
-
Nature's latest achievement: A new hope for the treatment of Alzheimer's disease-IL-3
Time of Update: 2021-09-05
Source: NetxPharmaAβ and neurofibrillary tangles in the brain of AD patients can cause nerve cell death, which is the root cause of cognitive decline .
Professor Tanzi mentioned that nerve cell death caused by neuroinflammation is at least 10 times higher than that caused by Aβ and neurofibrillary tangles .
-
Phase III clinical trial of bluebird gene therapy was halted by FDA
Time of Update: 2021-09-05
Article source: Medical Rubik's Cube InfoAuthor: QingwaBluebird announced its 2021Q2 financial report on August 10, in which it mentioned that the FDA has suspended its gene therapy elivaldogene autotemcel (eli-cel, Lenti-D™) for phase III adrenal leukodystrophy (CALD) Clinical trials .
-
The latest data on DNA damage therapy for pancreatic cancer: treatment reduces tumors in mice by more than 90%
Time of Update: 2021-09-05
LP-184 treatment in an in vivo mouse xenograft model of pancreatic cancer significantly shrinks the tumor (Source: Lantern)LP-184 is a DNA alkylating agent that exerts a therapeutic effect by destroying the DNA in cancer cells, which usually overexpress certain biomarkers .
-
Eisai launches Tazverik in Japan to treat EZH2 mutation-positive FL
Time of Update: 2021-09-05
The drug is indicated for the treatment of patients with relapsed or refractory EZH2 mutation-positive follicular lymphoma .
Study 206 enrolled patients with relapsed or refractory primary follicular lymphoma (FL) with positive mutations in the EZH2 gene.
-
New coronavirus RNA does not have the ability to integrate into the host genome
Time of Update: 2021-09-05
These results all indicate that the chimeric event of the novel coronavirus derived from the ribonucleic acid sequence and the host cell is false positive, and it mainly occurs during the construction of the library .
-
Fosun Kate CAR-T products are officially included in breakthrough treatment products
Time of Update: 2021-09-05
Text|Pharmaceutical Mission HillsOn August 17, the Center for Drug Evaluation (CDE) of the National Food and Drug Administration of China announced the latest announcement that the Akirensai injection declared by Fosun Kate has been included in the breakthrough therapeutic drug program and is intended to be used in the treatment of second-line or above systems Relapsed or refractory indolent non-Hodgkin's lymphoma after treatment .
-
Israel's oral new crown vaccine starts clinical testing in August
Time of Update: 2021-09-05
Olamed company uses this capsule technology for oral new crown vaccine .
The company's oral vaccine can target multiple components of the virus (including less mutated structures) and prevent more mutated strains of the new coronavirus .
-
The influence of the inclusion of social cost in the review of the drug classics on the economic evaluation results of rare diseases
Time of Update: 2021-09-05
Source: Value in HealthIn most of the studies carried out from the perspective of the whole society, no significant changes have been found in the economic evaluation results due to the high cost of treatment or the low quality-adjusted life obtained .
-
The domestic brand won the bid for the PTCA guide wire coronary artery device as the first place in the first group
Time of Update: 2021-09-05
On June 25 this year, the Inner Mongolia Medical Insurance Bureau issued the "Announcement of the Procurement Office of the Inter-provincial Alliance on Issuing the Procurement Documents for the Centralized Volume of Coronary Guide Wire (SJLM-14-HC2021-1)" .
-
Vegetarian food can also eat fatty liver. Long-term dieting, vegetarian food is not advisable
Time of Update: 2021-09-05
It is necessary to avoid liver-damaging behaviors such as long-term drinking, and at the same time, pay attention to control sugar, eat more dietary fiber, and exercise more .
-
Artificial intelligence program predicts 98.5% of human protein structure
Time of Update: 2021-09-05
"Alpha Fold" is an artificial intelligence program developed by "Deep Thinking" that can be used to predict protein structure .
The researchers also let "Alpha Fold" give a reliable prediction of 58% of the amino acid structural positions of the human proteome; among them, 35.
-
Nature's in-depth review: the past and future of protein kinase drug development
Time of Update: 2021-09-05
▲The timeline for the approval of protein kinase inhibitors (picture source: reference [1])Different modes and drug design for inhibiting protein kinase activityDifferent modes and drug design for inhibiting protein kinase activityAmong the approved small molecule kinase inhibitors, the most common mechanism of action is to inhibit the activity of protein kinases by binding to the ATP binding site of the target .
-
Alzheimer's disease antibody therapy application is submitted soon, Eli Lilly updates company structure
Time of Update: 2021-09-05
Patrik Jonsson will become President of Eli Lilly Immunology, responsible for the development and product launch of Eli Lilly’s dermatology, gastroenterology and rheumatology phase 3 pipelines .
Reference materials:[1] Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units.
